Duan Xiangke, Liu Wenfeng, Xiao Yanyu, Rao Man, Ji Liyin, Wan Xiaofu, Han Shuhong, Lin Zixun, Liu Haichen, Chen Peifen, Qiao Kun, Zheng Mingbin, Shen Jiayin, Zhou Yang, Asakawa Tetsuya, Xiao Minfeng, Lu Hongzhou
Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China.
BGI Research, Shenzhen, People's Republic of China.
Emerg Microbes Infect. 2025 Dec;14(1):2451048. doi: 10.1080/22221751.2025.2451048. Epub 2025 Jan 15.
() commonly induces refractory infection due to its multidrug-resistant nature. To date, there have been no reports on the application of phage treatment for infection. This study was conducted to explore the feasibility of phage application in treating refractory infection by collaborating with a 59-year-old male patient with a pulmonary infection of multidrug-resistant Our experiments included three domains: ) selection of the appropriate phage, ) verification of the efficacy and safety of the selected phage, ) confirmation of phage-bacteria interactions. Our results showed that phage Spe5P4 is appropriate for infection. Treatment with phage Spe5P4 showed good efficacy, manifested as amelioration of symptoms, hydrothorax examinations, and chest computed tomography findings. Phage treatment did not worsen hepatic and renal function, immunity-related indices, or indices of routine blood examination. It did not induce or deteriorate drug resistance of the involved antibiotics. Importantly, no adverse events were reported during the treatment or follow-up periods. Thus, phage treatment showed satisfactory safety. Finally, we found that phage treatment did not increase the bacterial load, cytotoxicity, virulence, or phage resistance of indicating satisfactory phage-bacteria interactions between Spe5P4 and , which are useful for the future application of phage Spe5P4 against This work provides evidence and a working basis for further application of phage Spe5P4 in treating refractory infections. We also provided a methodological basis for investigating clinical application of phage treatment against multidrug-resistant bacterial infections in the future.
（）由于其多重耐药性，通常会引发难治性感染。迄今为止，尚无关于噬菌体治疗该感染应用的报道。本研究通过与一名患有多重耐药性肺部感染的59岁男性患者合作，探讨噬菌体应用于治疗难治性该感染的可行性。我们的实验包括三个方面：）选择合适的噬菌体，）验证所选噬菌体的疗效和安全性，）确认噬菌体与细菌的相互作用。我们的结果表明，噬菌体Spe5P4适用于该感染。用噬菌体Spe5P4治疗显示出良好的疗效，表现为症状改善、胸腔检查和胸部计算机断层扫描结果。噬菌体治疗未使肝肾功能、免疫相关指标或血常规指标恶化。它没有诱导或加剧所涉及抗生素的耐药性。重要的是，在治疗期间或随访期间未报告不良事件。因此，噬菌体治疗显示出令人满意的安全性。最后，我们发现噬菌体治疗没有增加该细菌的载量、细胞毒性、毒力或噬菌体抗性，表明Spe5P4与该细菌之间存在令人满意的噬菌体 - 细菌相互作用，这对于噬菌体Spe5P4未来对抗该细菌的应用很有用。这项工作为噬菌体Spe5P4进一步应用于治疗难治性该感染提供了证据和工作基础。我们还为未来研究噬菌体治疗多重耐药细菌感染的临床应用提供了方法学基础。
